Literature DB >> 29566228

Site saturation mutagenesis of ribosomal protein L42 at 56th residue and application as a consecutive selection marker for cycloheximide resistance in yeast.

Jung-Hoon Bae1, Bong Hyun Sung1, Jung-Hoon Sohn1.   

Abstract

The 56th residue of ribosomal protein L42 (Rpl42) determines the sensitivity of yeast cells to the antibiotic cycloheximide (CYH). In this study, we identified the relationship between the 56th residue of Rpl42 and the function of the ribosome by site saturation mutagenesis. The resulting 20 RPL42 mutants harbouring one of 20 amino acids at the 56th residue were classified into five groups: sensitive to CYH (RPL42aP); weak resistance (RPL42aA, RPL42aM, RPL42aC, RPL42aN, RPL42aD, RPL42aS and RPL42aT), moderate resistance (RPL42aL, RPL42aI, RPL42aV, RPL42aG and RPL42aH), and strong resistance (RPL42aQ, RPL42aE, RPL42aR and RPL42aK) to CYH; and non-functional (RPL42aF, RPL42aY and RPL42aW). Three RPL42a mutants from each group, RPL42aA, RPL42aL and RPL42aQ, were used as CYH-resistant selection marker genes for the sequential transformation of CYH-sensitive yeast. A series of RPL42 mutants conferring different levels of resistance to CYH should be useful for the dose-dependent multiple selection of prototrophic industrial yeasts.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29566228     DOI: 10.1093/femsle/fny066

Source DB:  PubMed          Journal:  FEMS Microbiol Lett        ISSN: 0378-1097            Impact factor:   2.742


  2 in total

1.  E-site drug specificity of the human pathogen Candida albicans ribosome.

Authors:  Yury Zgadzay; Olga Kolosova; Artem Stetsenko; Cheng Wu; David Bruchlen; Konstantin Usachev; Shamil Validov; Lasse Jenner; Andrey Rogachev; Gulnara Yusupova; Matthew S Sachs; Albert Guskov; Marat Yusupov
Journal:  Sci Adv       Date:  2022-05-25       Impact factor: 14.957

2.  Genome editing enables reverse genetics of multicellular development in the choanoflagellate Salpingoeca rosetta.

Authors:  David S Booth; Nicole King
Journal:  Elife       Date:  2020-06-04       Impact factor: 8.140

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.